title: Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption.
abstract: Vemurafenib is a specific inhibitor of the V600E mutated BRAF protein kinase used for the treatment of unresectable or metastatic melanoma harboring this mutation. Multiple predictable side effects have been described with use of this targeted therapy, and implicate BRAF and mitogen activated protein kinase (MAPK) signaling pathways in their pathogenesis. Herein, we report the novel finding of an interface dermatitis in radiation recall and a keratosis pilaris-like clinical reaction in a patient treated with vemurafenib.
authors: Department of Dermatology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
authors: Inbal
authors: I
authors: Braunstein
authors: Tara C
authors: TC
authors: Gangadhar
authors: Rosalie
authors: R
authors: Elenitsas
authors: Emily Y
authors: EY
authors: Chu
mesh_terms: D000015:Abnormalities, Multiple / Q000139:chemically induced* / Q000473:pathology; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007644:Darier Disease / Q000139:chemically induced* / Q000473:pathology; D003875:Drug Eruptions / Q000473:pathology*; D005138:Eyebrows / Q000002:abnormalities* / Q000473:pathology; D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D013449:Sulfonamides / Q000009:adverse effects* / Q000627:therapeutic use; D000077484:Vemurafenib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib
keywords: dermatopathology; melanoma; radiation therapy